|
|||||
|
|
Cancer prevention by bovine lactoferrin: from animal studies to human trial |
|
| Authors: | Hiroyuki Tsuda Takahiro Kozu Gen Iinuma Yasuo Ohashi Yutaka Saito Daizo Saito Takayuki Akasu David B Alexander Mitsuru Futakuchi Katsumi Fukamachi Jiegou Xu Tadao Kakizoe Masaaki Iigo |
| Institution: | 1. Nanotoxicology Project, Graduate School of Medical Sciences, Nagoya City University, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan 7. Department of Molecular Toxicology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan 2. Cancer Screening Division, National Cancer Center, Research Center for Cancer Prevention and Screening, Tokyo, Japan 3. Diagnostic Radiology Division, National Cancer Center Hospital, Tokyo, Japan 4. Department of Biostatistics, School of Health Sciences and Nursing, The University of Tokyo, Tokyo, Japan 5. Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan 6. Colorectal Surgery Division, National Cancer Center Hospital, Tokyo, Japan 8. National Cancer Center, Tokyo, Japan |
| Abstract: | Colorectal cancer (CRC) is one of the most frequently diagnosed cancers and, despite improved colonoscopic screening, CRC is a leading cause of death from cancer. Administration of bovine lactoferrin (bLF) suppresses carcinogenesis in the colon and other organs of test animals, and recently it was shown that ingestion of bLF inhibits the growth of adenomatous polyps in human patients. Here we review work which established bLF as an anti-carcinogenic agent in laboratory animals and the results of a clinical trial which demonstrated that bLF can reduce the risk of colon carcinogenesis in humans. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |